| NCT06868628 | A Phase 2a Study of Foralumab Nasal in Patients With Multiple System Atrophy (MSA) | RECRUITING | PHASE2 | 2025-05-19 | 2027-04-01 | 2027-04-01 |
| NCT06890923 | Nasal Foralumab in Patients With Non-Active Secondary Progressive Multiple Sclerosis | RECRUITING | PHASE2 | 2025-03-04 | 2026-08-30 | 2026-04-30 |
| NCT06292923 | A Study of Nasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis Patients | RECRUITING | PHASE2 | 2023-11-15 | 2025-11 | 2025-11 |
| NCT05651269 | Milciclib in Combination With Gemcitabine in Advanced NSCLC | UNKNOWN | PHASE2 | 2023-03-15 | 2025-06 | 2024-12 |
| NCT05028946 | A Study of Oral Foralumab in Participants With Moderate to Severely Active Crohn's Disease | WITHDRAWN | PHASE1 | 2022-05-01 | 2023-11-07 | 2023-07-07 |
| NCT04983446 | In-patient COVID-19 Study of Intranasal Foralumab | WITHDRAWN | PHASE2 | 2022-04-30 | 2022-12-30 | 2022-10-30 |
| NCT05029609 | Phase 1b Multiple Ascending Dose Study of Foralumab in Primary and Secondary Progressive MS | WITHDRAWN | PHASE1 | 2021-10 | 2022-12 | 2022-11 |
| NCT06879067 | Safety, Tolerability and Immune Effects of the Nasal Foralumab in Healthy Human Volunteers | COMPLETED | PHASE1 | 2018-11-12 | 2020-11-09 | 2019-07-23 |
| NCT03291249 | Assessment of the Safety of Foralumab, an Oral Anti-CD3 Antibody, in Patients With NASH and T2DM | WITHDRAWN | PHASE2 | 2017-12-01 | 2019-06-01 | 2018-12-01 |
| NCT03109886 | Study of Milciclib in Patients With Unresectable/Metastatic Hepatocellular Carcinoma | COMPLETED | PHASE2 | 2017-07-12 | 2019-06-20 | 2019-05-16 |
| NCT01301391 | Study Of Oral PHA-848125AC In Patients With Malignant Thymoma Previously Treated With Multiple Lines Of Chemotherapy | TERMINATED | PHASE2 | 2011-02-02 | 2018-12-17 | 2017-05-31 |
| NCT01011439 | Phase II Study Of Oral PHA-848125AC In Patients With Thymic Carcinoma | TERMINATED | PHASE2 | 2010-02-22 | 2018-12-17 | 2017-05-31 |